Piperlongumine — Supplements
Natural alkaloid from Piper longum identified computationally as a dasatinib mimic; selectively induces apoptosis in senescent cells via ROS accumulation and GSH depletion.
Overview
Piperlongumine (PL) is a naturally occurring alkaloid isolated from Piper longum (long pepper), a plant used in Ayurvedic and traditional Southeast Asian medicine. It was originally identified as an anticancer compound that selectively kills cancer cells by exploiting their elevated oxidative stress. In 2016, researchers discovered that PL also selectively eliminates senescent cells — preferentially inducing apoptosis in radiation-, replication-, and oncogene-induced senescent human fibroblasts (WI-38) while sparing quiescent normal cells. A landmark March 2024 computational study in Scientific Reports identified PL as the top natural compound mimicking dasatinib's senolytic pharmacophore, suggesting it could potentially replace dasatinib in combination senolytic protocols. A January 2024 study identified synthetic PL analogs with 50-fold greater senolytic potency than the parent compound. The mechanism of PL senolytic activity is distinct from flavonoid senolytics (fisetin, quercetin, luteolin): rather than targeting BCL-2 family proteins directly, PL exploits the elevated ROS environment of senescent cells, inhibiting glutathione S-transferase pi (GST-π) and blocking NF-κB, creating an unsustainable oxidative burden that selectively triggers senescent cell death. PL has no completed Phase 2 human senolytic trials — its clinical use is currently investigational and evidence-extrapolating.
Indications
- Senescent cell clearance — investigational, preclinical
- Biological aging (adjunctive to established senolytic protocols)
- Combination senolytic protocols (potential dasatinib alternative)
- Pain and inflammation in Ayurvedic traditional use
Mechanism of Action
Piperlongumine inhibits glutathione S-transferase pi (GST-π), the primary enzyme responsible for neutralizing reactive oxygen species (ROS) in cancer and senescent cells. These cells operate near their oxidative stress threshold — GST-π inhibition tips them into catastrophic ROS accumulation and apoptosis while normal cells with lower baseline ROS tolerate the same inhibition
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Piperlongumine (standardized extract) | 10–50 mg | Two consecutive days per month (intermittent protocol) | Extrapolated from in vitro and animal data; senolytic intermittent protocol mirrors fisetin/D+Q approach; no validated human dose exists |
Evidence Grade
GRADE C
Safety & Contraindications
- No completed human clinical trials for senolytic indication as of 2025 — evidence is preclinical only
- Cytotoxic mechanism (ROS elevation) is not cell-type specific at high concentrations — narrow therapeutic window vs. normal cells
- GI irritant at higher doses — nausea, mucosal irritation possible (consistent with piperine-class alkaloids)
- CYP3A4 inhibitor — potential drug interactions with immunosuppressants, statins, hormones, anticoagulants
- Piperine co-administration (e.g., black pepper extract in same product) may alter absorption unpredictably
- Avoid in pregnancy — mutagenic signals in some in vitro studies; embryotoxic in animal models
- Most commercial supplements are crude Piper longum extracts — piperlongumine content unspecified; true piperlongumine-standardized supplements are rare